Ophthalmic Business News

Alcon has completed the acquisition of Aerie Pharmaceuticals, according to a press release.

Okyo Pharma has submitted an investigational new drug application to the FDA for OK-101 for the treatment of dry eye disease.

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better.

NEW YORK — In this Healio Video Perspective from OSN New York, Mina Sooch, founder and CEO of Ocuphire Pharma, discusses the company’s partnership with Viatris for the marketing and commercialization of the Nyxol eye drop.

AZR-MD-001 ophthalmic ointment showed positive 3-month safety and efficacy results for the treatment of meibomian gland dysfunction, according to a press release from Azura Ophthalmics.

The FDA has granted breakthrough therapy designation to Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric Bio.

NEW YORK — In this Healio Video Perspective from OSN New York, Richard L. Lindstrom, MD, provides an overview of current discussions surrounding disruptive innovation in ophthalmology.

CLS-AX demonstrated positive results in the phase 1/2a OASIS clinical trial in neovascular age-related macular degeneration, Clearside Biomedical announced in a press release.

NEW YORK — In a Healio Video Perspective from OSN New York, Aziz Mottiwala, of Tarsus Pharmaceuticals, discusses the FDA acceptance of the new drug application for TP-03 for the treatment of Demodex blepharitis.

Treasury Inflation Protected Securities, aka TIPS, provide investors with a return that is indexed to inflation over the life of the bond. With the sharp increase in inflation that began in 2021, many investors who own TIPS expected to see gains as a result.